Washington Post Publisher Will Lewis Steps Down After Layoffs 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
ATLANTA, Sept. 06, 2016 -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that it is delaying the time of its fourth quarter and fiscal year end 2016 earnings conference call and webcast while it concludes discussions involving the accounting treatment for its recent sale of its Inavir® royalty rights to HealthCare Royalty Partners. Aviragen will announce the new time for its conference call and webcast in the next several days.
About Aviragen Therapeutics, Inc.
Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: vapendavir, an oral treatment for human rhinovirus upper (HRV) respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor that has received Fast Track designation by the U.S. FDA, in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.aviragentherapeutics.com.
Contacts: Mark Colonnese Executive Vice President and Chief Financial Officer Aviragen Therapeutics, Inc. (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
